Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC

First global Phase 3 trial of first-line T-DXd in HER2-mutant NSCLC reports median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved...